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Abstract
As for a consolidated tradition, the 5th annual meeting of the Italian Network for Cancer Biotherapy
took place in the Certosa of Pontignano, a Tuscan monastery, on September 20–22, 2007. The
congress gathered more than 40 Italian leading groups representing academia, biotechnology and
pharmaceutical industry. Aim of the meeting was to share new advances in cancer bio-
immunotherapy and to promote their swift translation from pre-clinical research to clinical
applications. Several topics were covered including: a) molecular and cellular mechanisms of tumor
escape; b) therapeutic antibodies and recombinant constructs; c) clinical trials up-date and new
programs; d) National Cooperative Networks and their potential interactions; e) old and new
times in cancer immunology, an "amarcord". Here, we report the main issues discussed during the
meeting.
Introduction
The meeting took place in a monastery built by the
Carthusian Order on August 1343, located on the border
between the town-states of Florence and Siena. The Cer-
tosa of Pontignano preserved through the ages its original
atmosphere as an oasis of peace (Fig. 1). Nowadays, the
monastery is an University guesthouse where the annual
symposium of the NIBIT (acronym for the Network Ital-
iano per la Bioterapia dei Tumori – Italian Network for
Tumor Biotherapy) is organized. Tuscan landscape and
culinary specialties provided a peace of mind and body
that helped to reach the event goals.
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The increasing knowledge of the molecular mechanisms
involved in neoplastic transformation, of the biology of
cancer cells, and of the immunological mechanisms regu-
lating tumor-host interactions allows to identify and to
apply novel and eventually more effective bio-immuno-
therapeutic strategies in cancer patients [1].
However, for their optimal clinical development, and for
their swift translation from the laboratory to the clinical
setting, these new therapeutic approaches require a tight
cultural and operative interaction among different profes-
sionals involved in the clinical, regulatory and industrial
fields [2,3]. Thus, a shared effort is mandatory in order to
evaluate with due appropriateness, rapidity and scientific
rigor the biological and clinical efficacy of novel treat-
ments that become available. Nevertheless, while cancer
bio-immunotherapy is consolidating its role as an addi-
tional and powerful option in the comprehensive treat-
ment of cancer patients, it raises new and specific
procedural, ethical, and legal challenges to its broader
clinical application. Therefore, the efficient clinical devel-
opment and application of new modalities of cancer bio-
immunotherapy is often difficult for large research entities
and in most cases impossible for small research units [4].
On these premises, and to cope with a need strongly felt
by the Italian academic, industrial and regulatory commu-
nity, the NIBIT was created in 2004.
Main objectives of the NIBIT are
a) To promote and foster a stronger scientific and opera-
tive interaction among professionals belonging to
Academia, Biotech/Pharmaceutical Industry, Regulatory
Bodies;
b) To develop innovative, multi-center clinical studies of
cancer bio-immunotherapy at national level;
c) To set-up initiatives to inform patients about potentials
and limitations of cancer bio-immunotherapy and on
ongoing clinical trials [5].
Scientific welcome to the attendees
In his scientific welcome address, Lucio Luzzatto (Univer-
sity of Florence), Scientific Director of the Istituto Toscano
Tumori, made an excursus on scientific achievements in
the fields of human immunogenetics and cancer immu-
nology that are providing the molecular basis and the sci-
entific rationale to implement novel and eventually more
effective immunotherapeutic strategies in cancer patients.
Molecular and cellular mechanisms of tumor escape
(Chairs: Paola Zanovello and Paola Nisticò)
The presentation of Francesca Fallarino (University of
Perugia) focused on "Tumor escape from effector T cells" and
the immunoregulatory enzyme indoleamine 2,3 dioxyge-
nase (IDO). IDO has been associated with a wide variety
of human cancers because of its ability to potentiate sup-
pressing regulatory T-cells (T-regs) functions through the
catabolism of the essential aminoacid tryptophan. Addi-
tionally, it has been recently demonstrated that IDO acts
not only as an effector mechanisms of T-regs but also rep-
resents a way to generate new T-regs. These findings
underscore the importance of the clinical development of
IDO inhibitors for suppressing cancer progression [6].
Susanna Mandruzzato (University of Padua) presented
her experience in "Myeloid-derived suppressor cells: from
mouse to humans". Myeloid-derived suppressor cells
(MDSC) represent a population of myelo-monocytic cells
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lacking the markers of mature myeloid cells and express-
ing both Gr-1 and CD11b in mice. MDSCs bear a high
potential to suppress immune responses both in vitro and
in vivo. Mandruzzato showed that even if human MDSC
equivalents are not entirely known, granulocyte subpopu-
lations might be involved [7].
Epigenetic modifications generate heritable changes in
the expression of single genes or patterns of genes not
based on structural changes of the DNA sequence. Luca
Sigalotti (Centro di Riferimento Oncologico, Aviano) in
his presentation "Epigenetic intervention in tumor escape
mechanisms" demonstrated that hypomethylating agents
can modulate the expression of Cancer Testis Antigens
and their presentation on the cell surface of neoplastic
cells, as well as HLA class I antigens, leading to a more effi-
cient recognition of melanoma cells by cytotoxic T cells
(CTL) [8].
Licia Rivoltini (Istituto Nazionale Tumori, Milan) dis-
cussed on "Myeloid suppressor cells in melanoma patients",
reporting that microvesicles or exosomes released by
tumor cells and purified from patients' plasma induce
CD14+ HLA-DRlow cells with TGF-β-mediated suppres-
sive activity. Therefore, blocking their release by neoplas-
tic cells could improve immune recognition of cancer cells
[9].
Tumor-released factors targeting nuclear receptors of den-
dritic cells (DC) impair DC migration. Along this line,
Eduardo J. Villablanca (San Raffaele Scientific Institute,
Milan) discussed on "Impairment of DC migration by tumor-
released factors targeting DC nuclear receptors" pointing out
that the expression of chemokine receptor CCR7, that
guides mature DC from peripheral tissues to lymphoid
compartments, is inhibited on DC by soluble factors
released from 50% of the melanoma cells investigated in
vitro.
Keynote lecture
In his keynote lecture: "Immune cells within tumor microen-
vironment: fewer pros than cons", Mario Paolo Colombo
(Istituto Nazionale Tumori, Milan) focused on important
implications of the complex of mutual and dynamic rela-
tionships occurring between tumor and inflammatory or
stromal cells. Evidences exist that tumor progression is
supported rather than inhibited by inflammation, and
that tumor development is related to the phenotype, func-
tion and distribution of inflammatory cells within the
tumor mass. Along this line, he provided insights on the
potential impact of therapeutic strategies aimed at modi-
fying the population of tumor infiltrating cells [10].
Antibodies and recombinant constructs (Chairs: Enrico
Proietti and Michele Guida)
The presentation by Raffaella Giavazzi (Mario Negri
Institute, Milan) on "Angiogenetic targets and combination
therapies" provided evidence that combination regimens,
including two or more biological-vascular targeted inhib-
itors and conventional therapy, are more promising com-
pared to those based on the use of a single anti-
angiogenetic agent. Giavazzi also remarked that the phar-
macological delivery schedule and the time/sequence
should be carefully evaluated for the optimal administra-
tion of these combination treatments [11].
Angelo Corti (San Raffaele Scientific Institute, Milan) dis-
cussed the "Targeting tumor endothelium by NGR-cytokines
construct(s)". He described a therapeutic approach based
on the coupling of cytokines with peptides that contain
NGR, RGD or isoDGR domains, and that recognize recep-
tors expressed by angiogenetic vessels [12]. Bell-shaped
dose response curves have been observed with NGR-TNF,
NGR-TNF/EMAP-II and IFN-γ-NGR. Furthermore, Corti
presented ongoing and programmed clinical trials of
Phase I and Phase II with NGR-hTNF, utilized alone or in
combination with chemotherapy.
Anna Bagnato (Regina Elena Cancer Institute, Rome) pre-
sented data on "Molecular targeting of endothelin B receptor
(ETBR) in melanoma" demonstrating that ETBR expression
is associated with melanoma progression, and that block-
ing of ETBR by antagonists results in tumor growth inhibi-
tion and in a reduced expression of endothelial markers.
Thus, new strategies using specific ETBR antagonists could
provide an improved approach to the treatment of
melanoma. Along this line, clinical trials with a dual (ETA
and ETB) endothelin receptor antagonist (Bosentan) that
acts by competitively and specifically binding to ETA and
ETB receptor sites in the endothelium and vascular smooth
muscle, are ongoing in metastatic melanoma patients
[13].
In her presentation "Targeting Her2 in breast cancer" Elda
Tagliabue  (Istituto Nazionale Tumori, Milan) showed
that Antibody-Dependent Cellular Cytotoxicity (ADCC)
constitutes a mechanism involved in the therapeutic activ-
ity of Trastuzumab; however, quantity and lytic efficiency
of CD16+CD56+ lymphocytes are major factors for the
ADCC heterogeneity observed in treated patients [14].
Additionally, the efficacy of Trastuzumab also depends on
its cytostatic effect. An Italian multi-center retrospective
and prospective study, called DEMETRA, on 444 women
with metastatic HER2-positive breast carcinoma treated
with Trastuzumab has been opened to assess clinical
responses, metastatic sites with better susceptibility to
treatment, the best chemotherapeutic combination(s)
with Trastuzumab and its toxic effects.Journal of Translational Medicine 2008, 6:8 http://www.translational-medicine.com/content/6/1/8
Page 4 of 8
(page number not for citation purposes)
National Cooperative Networks: potential interac-
tions?(Chairs: Ruggero Ridolfi and Vincenzo Russo)
Cancer represents more than 200 diseases, and for its best
cure it clearly requires a multi-disciplinary knowledge and
approach. This session was based on possible and
required interplays between Italian Networks for cancer
treatment. Four Italian groups were invited to explain the
aim of their associations and to foresee potential pre-clin-
ical and clinical interactions with the NIBIT: Piero Picci
(Bologna) for the "Italian Sarcoma Group" [15],  Paolo
Ascierto (Naples) for the "Italian Melanoma Intergroup"
[16], Paolo Pedrazzoli (Milan) for the "Italian Bone Mar-
row Transplant Group" [17] and Nicoletta Zilembo
(Milan) for the "Italian Trials in Medical Oncology" [18].
The main goals of these interactions are to make uniform
the clinical diagnosis and therapeutic protocols, improve
patient wellness, foster collaboration between national
and international Institutions, provide meeting opportu-
nities to exchange and teach advances in cancer treat-
ments.
Old and new times in cancer immunology: an "amar-
cord" (Chairs: Mario Paolo Colombo, Paolo Dellabona
and Pierluigi Lollini)
Among the aims of the meeting, one was to provide an
overview in specific areas of cancer research in the last two
decades. It was deemed important to deliver lectures for
the next generation of cancer researchers and clinicians, to
foster the understanding of ongoing clinical trials and
research projects destinations. Six senior lecturers realized
this "tour de force" to explain the evolution of cancer care
and their personal contribution into it.
Giorgio Parmiani (San Raffaele Scientific Institute,
Milan) delivered the talk "From tumor immunology to immu-
notherapy: the ups and downs of the last two decades". In par-
ticular, the presentation was focused on immune-
surveillance, tumor specific transplantation antigens, IL-2
cytokine therapy, human tumor antigens and vaccination
with peptides/proteins [19].
Pier Giorgio Natali (Regina Elena Cancer Institute,
Rome) with the presentation "Tumor immunophenotyping:
a two-way ticket between laboratory and the clinic" argued on
the necessity to continue the expansion of the banks of
human tissues to further understand cancer biology, and
to finally achieve the molecular classification by gene
expression profiling of all human cancer types [20].
The presentation by Sergio Romagnani (University of
Florence) "Effectors and regulatory T cells in man" showed
how CD4+ cells are important in cancer treatment,
through their functional role as effector, helper and regu-
latory cells. He also demonstrated that human Th17 cells,
a subset of interleukin 17-producing T helper cells, that
could play a key role in autoimmune disease, are different
from mouse Th17 cells [21].
Alberto Amadori (University of Padua) with "B cell activa-
tion: deeds, misdeeds, and serendipity" explained how inter-
actions between B and T cells are crucial for the immune
system. Then, he talked on the role of hypoxia in human
lymphomas, providing evidence that it inhibits macro-
phages and monocytes migration and up-regulates
CXCR4 surface expression in B-cell lymphomas [22].
The presentation by Lorenzo Moretta (University of
Genoa) "The NK in cancer: A new tool for cancer therapy?"
provided insights on a new approach for the treatment of
acute leukaemia by using NK cells-based therapy. He
demonstrated that the size of the alloreactive NK cell sub-
set parallels the degree of NK cytotoxicity against leukae-
mic cells [23].
Guido Forni (University of Turin) with "Mind the mouse:
drawbacks and illuminations by experimental models" pointed
out the still controversial issue of whether genetically
engineered mice could be an appropriate and reliable
model for cancer immunity [24].
Keynote lecture
Paolo Bruzzi (National Institute for Cancer Research,
Genoa) opened the session on clinical studies delivering
the keynote lecture: "Methodological challenges in trials of
novel anticancer therapies". A clinical study in cancer
patients should be designed remembering Sackett's
words: "Most controversies on the interpretation of the
results of clinical trials derive from disagreements or
ambiguities on the aims of the trial". In fact, the identifi-
cation of its aims is the most important phase of a clinical
trial design. Clinicians, biologists and statistician should
work together to specifically define the primary endpoints
of a clinical study, in order to not misinterpret its results
only because they do not hit the bull's eye [25].
Clinical studies: Up-date and New Programs (Chairs:
Giorgio Parmiani and Michele Maio)
The presentation by Enrico Proietti (Istituto Superiore
Sanità, Rome) on "Chemo-immunotherapy: an advanced
approach in melanoma" provided evidence that chemo-
immunotherapy induces a plethora of immunomodulat-
ing changes in PBMCs. Microarray and Real Time PCR
data, on PBMCs of tumor-resected patients treated with
Dacarbazine (DTIC), demonstrate that treatment modu-
lates the levels of expression of homeostatic cytokines like
IL-2 and IL-15 [26].Journal of Translational Medicine 2008, 6:8 http://www.translational-medicine.com/content/6/1/8
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Roberto Camerini (Sigma Tau, Rome) with "Thymosin
alpha-1 in metastatic melanoma" described a large first-line,
randomized, dose-finding, phase II Study on Thymosin
alpha 1 (Tα1) plus DTIC, with or without Interferon alpha
(IFN-α), vs. DTIC plus IFN-α in stage IV melanoma
patients. This study showed that the best candidate regi-
men for a future phase III trial is DTIC + Thymosin 3.2 mg
since, opposite to the DTIC + IFN-α control arm, it
reached the number of tumor responses required to reject
the null hypothesis (at least 9 responses) [27].
Based on the mouse model data demonstrating that Sal-
monella infected tumor cells are killed by anti-salmonella
specific T cells, Francesco Ferrucci (European Institute of
Oncology, Milan) presented a "Pilot phase II study of a com-
bined immunotherapy protocol based on oral vaccination and
direct intratumoral injection of Salmonella Typhi in metastatic
cutaneous melanoma patients". The study is ongoing and
nine patients have been enrolled so far [28].
Barbara Capaccetti (Pfizer Oncology, Rome) presented
on "CTLA-4 in metastatic melanoma", a Pfizer designed
phase I study, then moved to phase II, in which advanced
and high risk melanoma patients were treated with the
anti-CTLA-4 monoclonal antibody (Tremelimumab) at
varying dose levels. Primary objective of this study was to
assess safety and tolerability of the drug. Results show that
not only Tremelimumab is manageable for safety profile
and that the schedule of administration is very suitable,
but, most important, median survival was 15,9 months
for all dose group combined [29].
Cosimo Paga (Bristol-Myers Squibb, Rome) also reported
on "CTLA-4 in metastatic melanoma". Bristol-Myers Squibb
(BMS) sponsored several clinical trials with an anti-CTLA-
4 monoclonal antibody (Ipilimumab) administered as
monotherapy or in combination with DTIC in melanoma
patients. It has been observed that the administration of
Ipilimumab, alone or in combination with DTIC,
increases the overall survival of patients vs. DTIC alone.
For safety profile, adverse events are characteristic of Ipili-
mumab treatment and probably result from its mecha-
nism of action; however, they are usually reversible,
linked to drug exposure, and appear to correlate with clin-
ical response [30].
Luana Calabrò (University Hospital of Siena) presented a
new study on the use of: "CTLA-4 in malignant mesotheli-
oma". Malignant mesothelioma (MM) is a neoplasm
endowed by a very poor prognosis, whose incidence has
increased steadily and progressively over the last 30 years.
As there is no standard treatment, MM can be considered
a "model disease" to explore new therapeutic regimens.
Pre-clinical and clinical studies have shown that MM
patients can mount a tumor-specific immune response;
however, this immune activation does not result in tumor
rejection, likely because the mesothelioma microenviron-
ment comprises cytokines and T-reg cells that effectively
suppress immune responses. Thus, a second line phase II
clinical trial with Tremelimumab has been designed to
treat patients with unresectable MM. Primary aim of the
study will be to assess the rate of objective clinical
responses (complete and partial responses); while sec-
ondary end points will be to define toxicity profile, to
assess the progression free survival, and to evaluate quali-
tative and quantitative changes in cellular and humoral
responses [31].
Francesco Leone (University of Turin) described the
upcoming trial: "CTLA-4 in pancreatic cancer". Blocking of
CTLA-4 with anti-CTLA-4 antibodies may represent a way
to break the peripheral immunologic tolerance in pancre-
atic cancer patients and to restore an adequate immune
response against the tumor. The trial will be conducted as
a prelude to a planned phase II trial of anti-CTLA-4 anti-
body in combination with gemcitabine that has shown
immune-enhancing effects. Primary endpoint of the trial
is to define safety and maximum tolerated dose of the
drug.
In his presentation "Adjuvant vaccination in prostate cancer"
Andrea Marrari (Istituto Nazionale Tumori, Milan) sum-
marized an ongoing trial in which multiple peptides
derived from the prostatic associated-antigen (PSA) are
administrated in association with Montanide ISA51 to
patients with relapsing disease after surgery or radiother-
apy. The 16 enrolled patients have completed the first
cycle of vaccination, whereas only 9 completed the entire
schedule. Three patients developed an immunological
response to the vaccine, while 5 of them showed a stabili-
zation or reduction of PSA levels [32].
Federica Danzi (Glaxo Smith-Kline, Italy) reported on:
"MAGE-3 vaccination in lung cancer". MAGE-3 is an immu-
nogenic Cancer Testis Antigen whose expression is associ-
ated with a poor prognosis in lung cancer. A recombinant
MAGE-3 protein was administered in phase I/II clinical
trials in non-small cell lung (NSCL) cancer patients. Based
on the promising clinical results obtained, a multi-center
double blind randomized phase III study called MAGE-A3
as  Adjuvant non-small cell lunG  cancerR Immuno-
Therapy (MAGRIT) was designed. 2270 patients with
MAGE-3 positive NSCL cancer of stage IB, II or IIIA will be
enrolled after surgery in four arms receiving: i) platinum-
based chemotherapy and placebo; ii) platinum-based
chemotherapy and MAGE-3 protein; iii) placebo; iiii)
MAGE-3 protein. Primary endpoint of the study is the
assessment of the disease free-survival.Journal of Translational Medicine 2008, 6:8 http://www.translational-medicine.com/content/6/1/8
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Luigi Aurisicchio (Merck, Rome) described a novel
mouse model for the: "Enhancement of cancer vaccines effi-
cacy". A vaccination study in Balb/neuT mice demon-
strated that the combination of CEA/HER2 DNA-based
vaccine with an immuno-modulator (i.e., IMO-1, a TRL9
agonist) enhanced the immune response in mice, retard-
ing and/or blocking tumor growth. These evidences once
again strengthened the importance of immunomodula-
tory agents in cancer vaccinations. The results obtained
from this pre-clinical study could help to redesign disap-
pointing past clinical studies based on DNA vaccination.
Paola Queirolo (National Institute for Cancer Research,
Genoa) presented the study: "High dose interferon-α2b
(HDI) or PEG-Intron in combination with a multipeptide-
based vaccine in metastatic (M1a, M1b AJCC) melanoma
patients. A phase II randomized NIBIT study". This is the first
clinical trial designed within the NIBIT. The study com-
prises three arms: the first in which metastatic melanoma
patients will receive HDI plus a multipeptide vaccine (i.e.,
gp100, NY-ESO-1 and survivin derived peptides emulsi-
fied in Montanide); the second in which patients will be
treated with pegylated interferon-α2b (PEG-Intron) plus
the multipeptide vaccine; the third in which patients will
receive PEG-Intron alone. The primary aims of the study
are to evaluate the feasibility of the procedure and to
investigate tumor-specific humoral and cellular immune
responses [33].
Lorenzo Pilla (Istituto Nazionale Tumori, Milan) pre-
sented preliminary findings on the ongoing trial "Multi-
peptide-based vaccination in melanoma". Currently, no
validated therapeutic regimens are available for stage II/III
melanoma patients who underwent radical surgery and
are at high risk of disease relapse. On this basis, a phase II
randomized trial is being carried out to determine the
immunologic and clinical effect of a vaccine based on
immunogenic peptides from MART-1:26–35 (27 L),
gp100: 209–217 (210 M), NY-ESO-1: 157–165 V and sur-
vivin-1: 96–104, administered in combination with Mon-
tanide ISA 51 and IL-2 as adjuvant. Preliminary results
show that vaccination increased the levels of CTL specific
for all the antigenic peptides utilized in the study. An anal-
ysis of the T-reg population is ongoing to see its variation
in the blood and vaccine-draining lymph nodes.
Gaetano Finocchiaro (Fondazione IRCCS Istituto Neuro-
logico Besta, Milan) delivered the talk on "Vaccination with
cancer stem cells (CSC) in glioblastoma (GB)". CSC were
derived from GB and grown in vitro with specific growth
factors (i.e., EGF and bFGF) to form neurospheres. In vivo
experiments demonstrated that these neurospheres have
the potential to express glial and/or neuronal markers and
form highly infiltrating GB into the brain of immune-defi-
cient mice. Furthermore, the use of DC loaded with lysates
from GB cells or neurospheres as therapeutic vaccines can
arrest tumor growth and retard its relapse in mice grafted
with murine GB cells. A phase I clinical trial, using autol-
ogous DC loaded with lysate from patient's tumor
(DCVax®-Brain manufacturing), was administered after
surgery and radiotherapy, concurrent with chemotherapy
to 18 patients with GB multiform. As the vaccine did not
present toxicity and significantly extended progression
free survival and increased overall survival, the clinical
trial moved to phase II [34].
Marco Bregni (San Raffaele Scientific Institute, Milan)
reported on: "Intraperitoneal therapy with dendritic cells in
ovarian cancer". The induction of tumor cell death with
chemotherapeutic agents can induce a tumor-specific
immune response if appropriate adjuvant signals are
delivered with an appropriate timing. Ovarian cancer rep-
resents a suitable model for intraperitoneal therapy with
DCs, as in 80% of cases the disease is confined to the per-
itoneum. Along this line, a proposal for a pilot study in
advanced ovarian cancer patients with recurrent disease
was presented. DCs and natural killer/lymphokine-acti-
vated killer (NK/LAK) cells, derived from the enrolled
patients and activated in vitro for 6 days, will be adminis-
tered 48 hours after standard chemotherapy. Primary
objective of this study will be the assessment of the feasi-
bility and safety of the procedure. Secondary endpoints
will be the definition of specific anti-tumor immune
responses, clinical response rate and time to progression
free-survival of patients.
Franco Venanzi (University of Camerino) presented on
"Do tumor endothelial marker 8 (TEM8) gene-expression lev-
els impact clinical outcome in dendritic cells-based cancer vac-
cination?". TEM8, a membrane anthracis receptor, is
selectively over-expressed on tumor cells, tumor endothe-
lium and in DCs maturated in the presence of tumor cells.
A retrospective study in melanoma patients vaccinated
with DCs loaded with autologous tumor lysate showed
that increased levels of TEM8 expression in DCs vaccine
preparations correlate with disease progression [35].
These preliminary findings suggest that high levels of
TEM8 expression might represent an exclusion criterion
for DC-based cancer vaccination.
Daniela Montagna (University of Pavia) talked about:
"Evaluation of feasibility and safety of the infusion of autolo-
gous tumor-reactive T cells in sarcoma patients". The phase I
study presented was conducted in sarcoma patients refrac-
tory to chemotherapy or relapsing during chemotherapy.
The protocol was based on ex vivo induction of allogeneic
or autologous CTL lines activated with tumor cells and
then re-infused to the patient. The study showed that the
treatment is well tolerated and that it is also capable to
induce stabilization of disease and to prolong overall sur-Journal of Translational Medicine 2008, 6:8 http://www.translational-medicine.com/content/6/1/8
Page 7 of 8
(page number not for citation purposes)
vival. Optimization of this immunotherapeutic strategy is
currently under investigation [36].
Conclusion
During the 5th meeting of the NIBIT, scientists represent-
ing academia, biotechnology and pharmaceutical indus-
try put together their ideas, results and their good will to
make real translational cancer biotherapy. Here, we insist
on the necessity to continue and strengthen this collabo-
ration both nationally and internationally, [37] and we
invite basic scientist, clinical researchers and industries to
contact us and join the network to overstep obstacles in
cancer care improvement [38].
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